Trials / Sponsors / Academic and Community Cancer Research United
Academic and Community Cancer Research United
Academic / Other · 50 registered clinical trials — 6 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma | Phase 2 | 2024-10-02 |
| Recruiting | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19 Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 2 | 2024-01-31 |
| Recruiting | Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | 2024-01-04 |
| Withdrawn | Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cance Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Phase 2 | 2023-10-31 |
| Active Not Recruiting | Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | 2023-07-01 |
| Terminated | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezoliz BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma | Phase 2 | 2023-01-19 |
| Active Not Recruiting | Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | 2022-12-08 |
| Recruiting | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | 2022-05-27 |
| Active Not Recruiting | PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | 2022-05-16 |
| Recruiting | Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma | Phase 2 | 2021-08-03 |
| Recruiting | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Adv Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8 | Phase 2 | 2021-06-16 |
| Terminated | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refrac Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | 2021-04-01 |
| Terminated | Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Chola Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Unresectable Cholangiocarcinoma | Phase 1 | 2021-01-25 |
| Withdrawn | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 201 Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm, Chronic Lymphocytic Leukemia | Phase 2 | 2020-11-23 |
| Terminated | Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutat Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Recurrent Pancreatic Carcinoma | Phase 2 | 2020-11-16 |
| Withdrawn | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma | Phase 2 | 2020-11-11 |
| Unknown | Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation | Phase 2 | 2020-08-31 |
| Withdrawn | Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Recurrent Plasma Cell Myeloma | Phase 2 | 2020-08-07 |
| Unknown | Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma | Phase 2 | 2020-06-24 |
| Active Not Recruiting | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type C Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma | Phase 2 | 2020-04-24 |
| Terminated | Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Tr Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8 | — | 2020-04-20 |
| Active Not Recruiting | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma | Phase 2 | 2020-03-03 |
| Unknown | TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Resid Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7 | Phase 2 | 2020-02-20 |
| Completed | Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectab Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8 | Phase 2 | 2019-10-29 |
| Active Not Recruiting | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pan Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | 2018-11-02 |
| Terminated | Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastat Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 2 | 2018-02-16 |
| Completed | Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic Thyroid Gland Follicular Carcinoma | Phase 2 | 2018-02-07 |
| Active Not Recruiting | Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma | Phase 2 | 2017-10-13 |
| Completed | Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Antico Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm | Phase 3 | 2017-07-14 |
| Completed | Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colo Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma | Phase 2 | 2017-07-07 |
| Active Not Recruiting | Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Tr Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7 | Phase 2 | 2017-03-31 |
| Active Not Recruiting | Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Metastatic Small Intestinal Adenocarcinoma, Recurrent Small Intestinal Carcinoma, Unresectable Small Intestinal Carcinoma | Phase 2 | 2017-03-24 |
| Completed | Oxybutynin Chloride in Managing Hot Flashes Breast Carcinoma, Ductal Breast Carcinoma In Situ, Hot Flashes | Phase 3 | 2016-12-09 |
| Active Not Recruiting | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphom Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Phase 1 / Phase 2 | 2016-05-20 |
| Active Not Recruiting | Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma | Phase 2 | 2016-05-13 |
| Completed | Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Breast Carcinoma | N/A | 2015-12-23 |
| Completed | Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism Cerebral Vein Thrombosis, Deep Vein Thrombosis, Gonadal Thrombosis | Phase 3 | 2015-11-20 |
| Completed | Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma | Phase 2 | 2015-05-04 |
| Completed | Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer Colon Adenocarcinoma, Rectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v7 | Phase 2 | 2015-03-27 |
| Completed | Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7 | Phase 2 | 2014-12-12 |
| Completed | Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients Wi Acute Pain, Breast Carcinoma, Peripheral Neuropathy | Phase 2 | 2014-11-01 |
| Withdrawn | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Gastrinoma, Glucagonoma, Insulinoma | Phase 2 | 2014-10-01 |
| Terminated | Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Wh Adenocarcinoma of the Gastroesophageal Junction, Stage IIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma | Phase 2 | 2014-09-01 |
| Suspended | Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage III Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma | Phase 3 | 2014-01-17 |
| Completed | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma Metastatic Melanoma, Mucosal Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 2 | 2013-10-18 |
| Completed | Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab Advanced Malignant Neoplasm, Dermatologic Complication | Phase 2 | 2012-08-31 |
| Completed | Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Can EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R, Lung Non-Squamous Non-Small Cell Carcinoma | Phase 2 | 2012-03-16 |
| Completed | Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel Pain, Peripheral Neuropathy | Phase 2 | 2012-01-01 |
| Completed | White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer Unspecified Adult Solid Tumor, Protocol Specific | N/A | 2009-07-01 |
| Completed | Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Ho Lymphoma | Phase 2 | 2005-03-01 |